Diabetes Clinical Trials in Tulsa
View 13 new treatments for Diabetes in Tulsa, OK, and nearby areas, such as Broken Arrow. Every day, Power helps hundreds of diabetes patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Orforglipron vs Dapagliflozin for Type 2 Diabetes
Eli Lilly Clinic, Tulsa + 1 more
This trial is testing two medications, orforglipron and dapagliflozin, to see which one better controls blood sugar in people with type 2 diabetes who are not well-managed on metformin alone. Orforglipron lowers blood sugar levels, while dapagliflozin helps remove sugar through urine. The study will last several months. Dapagliflozin has been shown to improve blood sugar control in various studies.Show More
Verified
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
ILUVIEN® Implant for Diabetic Macular Edema
Alimera Sciences Clinic, Tulsa + 1 more
This is a randomized, masked, active-controlled, parallel-group, multi-center study that will assess the efficacy of ILUVIEN as a baseline therapy in the treatment of Center Involving DME (CI-DME). The study will enroll patients who are either treatment naïve or have not received any DME treatments for the preceding 12 months as documented in medical records. Patients who received DME treatment \>12 months before screening, must not have received \>4 intravitreal injections. The study will compare 2 treatment regimens: ILUVIEN intravitreal implant (0.19 mg) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL), compared to intravitreal aflibercept loading dose (2 mg administered by intravitreal injection every 4 weeks for 5 consecutive doses) followed by supplemental aflibercept as needed per protocol criteria (2 mg/0.05 mL).Show More
Waitlist
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Samer Kaba, MD
Study Chair
Naltrexone + Bupropion for Obesity
Currax Clinic, Tulsa + 1 more
This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Retatrutide vs Semaglutide for Type 2 Diabetes
Eli Lilly Clinic, Tulsa + 1 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Retatrutide for Type 2 Diabetes
Eli Lilly Clinic, Tulsa + 1 more
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.Show More
Recruiting
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Orforglipron for Type 2 Diabetes and Obesity
Eli Lilly Clinic, Tulsa + 1 more
This trial is testing a new diabetes medication called orforglipron to see if it is safer and more effective than insulin in people with type 2 diabetes who are overweight or obese and at higher risk for heart problems. The study will last several years and involve multiple visits.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Lanifibranor for Nonalcoholic Steatohepatitis (NASH)
Inventiva Clinic, Tulsa + 1 more
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Recruiting
Phase 3
Est. 3 - 12 Weeks
Sven Francque, MD
Principal Investigator
Phage Therapy for Diabetic Foot Osteomyelitis
Adaptive Phage Clinic, Tulsa + 1 more
This is a phase IIa randomized trial designed to evaluate bacteriophage therapy in patients with diabetic foot osteomyelitis.
Recruiting
Phase 2
Est. 5 - 8 Weeks
Edward Fang
Principal Investigator
HTD1801 for Non-alcoholic Fatty Liver Disease
HighTide Biopharma Clinic, Tulsa + 1 more
This trial is testing HTD1801, a medication, to see if it can help adults with NASH and liver fibrosis who also have type 2 diabetes or pre-diabetes. The goal is to see if the medication can reduce liver inflammation and scarring, thereby improving liver health.Show More
Recruiting
Phase 2
Est. 4 - 6 Weeks
Adrian Di Bisceglie, MD, FACP, FAASLD
Study Director
Multiple Treatments for Chronic Pain
Eli Lilly Clinic, Tulsa + 1 more
This trial is testing different treatments for chronic pain in patients with knee osteoarthritis, chronic low back pain, and diabetic nerve pain. It aims to find effective ways to reduce their chronic pain.Show More
Recruiting
Phase 2
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Page 1 of 2
Frequently Asked Questions
Explore related conditions